Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy She is a known case of MD with history of gradual onset of progressive lower extremities muscle weakness noticed since 27 years of age with complaints of imbalance while walking foot drop and difficulty in stair case climbing So she was investigated and muscle biopsy confirmed diagnosis of MD After Stem Cell Therapy 1 Stamina has increased Exercise tolerance has improved 2 She can lift her leg more up while in standing 3 Hip ...

By: neurogenbsi

Follow this link:
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy - Video

Prolotherapy | PRP | Stem Cell Therapy | The Prolotherapy Institute - prolotherapyinstitute.com
Prolotherapy | PRP | Stem Cell Therapy | The Prolotherapy Institute prolotherapyinstitutecom. Uploaded by Guillermo Mata on Mar 11 2013. Suffering from chronic pain Dr Darrow can help Prolotherapy | PRP | Stem Cell Therapy in Southern California Call The Prolotherapy Institute today Call Us Today to Make an Appointment800 7342210.

By: Guillermo Mata

See the original post:
Prolotherapy | PRP | Stem Cell Therapy | The Prolotherapy Institute - prolotherapyinstitute.com - Video

With its growing popularity in the country, the so-called stem cell therapy, which was recently approved by the Department of Health (DOH), is now available in Davao City.

Dr. Luz Acosta, a Davao-born physician specializing in Ophthalmology, Oculoplastic Reconstructive Surgery, Cosmetic Surgery and recently Stem Cell Treatment, conducts the procedure after acquiring equipment from Australia and the USA. She is supported by a team that includes cardiologists, internists, and anesthesiologists who administer the laboratory tests and cardiopulmonary clearance to determine if an individual can safely undergo stem cell therapy. Having trained in this discipline abroad, she recently decided to offer this treatment after it was approved by the DoH.

As a founding member of the Philippine Society for Stem Cell Medicine that was only established last January 18, 2013 with DOH Sec. Dr. Enrique Ona as its honorary chair, Acosta is joined by doctors Jose Sabili, Melchor Santos, Christian Mancao, Leo Olarte, Bu Castro, Oscar Tinio, and Almond Derla as well as Mr. Rico Colayco as organizers of the society.

"This means that the Philippine Society for Stem Cell Medicine is the regulating body for the practice of stem cell treatment in the country," Acosta says. "Stem cell therapy is legal and safe for every medically cleared patient who wants to undergo such treatment to be rejuvenated and treated of his/her illnesses and diseases."

Acosta said that based on what was stipulated in the approved directions for stem cell therapy, the stem cell could just come from the person himself and not from the other sources like black sheep or aborted fetus, adding that sources of stem cells are fats, blood, bone marrow and umbilical cord.

"It could take five to six hours for one to undergo stem cell therapy. Harvesting is done in the first two hours, then another one to two hours for stem cell processing and activation, and the last one to two hours for treatment of stem cells back to the same patient," she said.

Popular personalities who have already publicly admitted that they had undergone stem cell therapy are former President Joseph Estrada, Senate President Juan Ponce Enrile and former Senator Ernesto Maceda, who said that they spent millions to pay for the treatment.

But Acosta said that it could be a lot cheaper here than abroad, as the cost of treatment will be in accordance to the guidelines of the Phil. Society for Stem Cell Medicine.

She said there have been very good clinical outcomes from stem cell treatments on autism, auto-immune diseases, cerebral palsy, diabetes, heart disease, liver cirrhosis, macular degeneration, multiple sclerosis, nerve damage, osteoarthritis, spinal cord injury and stroke.

"But we have to clarify here that we are not claiming stem cell therapy as a cure for cancer, though it can alleviate pain and improve patients' wellbeing while undergoing cancer therapy," she said.

See more here:
Stem Cell Therapy Now In Davao

By Cheche V. Moral

I DID it because it worked on my wifes cousin, and because of what I read about it, says Joe Concepcion of his stem-cell therapy. ALANAH TORRALBA

Last of two parts

Jose S. Concepcion Jr., at 81, still goes to the office daily, and, to his wifes chagrin, is quite restless and bullheaded, sour if he has nothing to keep himself busy.

He does crazy things! Like, if he gets hold of a book, hell bring it and photocopy everything, says Marivic Concepcion, who has been married for 56 years to the RFM Corp. chair, Namfrel (National Citizens Movement for Free Election) founder and former trade secretary. He needs a caregiver but he wont allow it. He could fall!

Her husband, however, insists he feels excellent. I feel so good when I wake up. I dont feel tired, says the activist known to many as Joecon.

Concepcion attributes this renewed strength and vigor to a procedure he had undergone not long ago, and of which he has been a vocal and unpaid advocate: stem-cell therapy.

Astonishing effects

The tycoon received his treatment from a German doctor named Christoph Ganss, who comes to the Philippines every three or four months to speak about his company and the benefits of stem-cell banking, according to the Concepcions. Ganss is the founder of Ticeba (Tissue & Cell Banking), a tissue bank for stem cells and laboratory in Heidelberg.

The couple heard of Dr. Ganss from Ms Concepcions cousin who underwent the treatment in Germany.

Follow this link:
Jose “Joecon” Concepcion Jr: ‘I’m now a believer in stem-cell therapy. The proof is me!’

VAIL The Vail Athletic Club, part of the Vail Vitality Center wellness experience at Vail Mountain Lodge, introduces a lecture which offers an in-depth look at new developments in cellular therapy for the treatment of joint pain. Stem Cell Therapy is a groundbreaking procedure that uses a patient's own stem cells to repair or replace damaged joint tissue. Dr. Scott Brandt of ThriveMD in Edwards is one of few physicians in the country trained in this procedure. Brandt will present details about this innovative new therapy at the Vail Athletic Club on Friday at 6 p.m.

Stem cell therapy is a minimally invasive procedure that begins with harvesting a patient's stem cells from his or her own fat reserves most often from the abdominal region. The tissue is isolated in a state-of-the-art cell-processing laboratory. The cells are then injected into the damaged joint using a minimally invasive technique with the assistance of fluoroscopic guidance. Once injected, the cells can sense proteins generated from cartilage damage and, in response, those cells have the ability to make chondrocytes cells found in healthy cartilage. This new procedure relieves the pain and limitations of arthritic joint disease without resorting to an invasive joint replacement surgery.

Brandt will discuss the process of isolating autologous adipose derived stem cells, the details of the procedure, and answer questions about this treatment for cartilage, ligament and tendon injuries.

For more information or to register call 970-476-7960. The lecture is offered as a fundraiser for the Eagle County Education Foundation and a $15 donation is suggested. Advance reservations are required and space is limited.

Continued here:
Learn more about stem cell therapy at Vail Athletic Club Friday

Autism Improvement After Stem Cell Therapy in Mumbai India
He is a known case of Autism with history of full term normal delivery, cried immediately after birth. He had near normal motor milestones with delayed speech. On examination, he has poor eye contact, poor concentration, poor attention span, poor language command. He is stubborn and aggressive (decreased with rehabilitation). He goes to normal school and had good memory but poor in social communication. On ISAA scale he scores 90. On WeeFIM, he scores 77. After Stem Cell Therapy Psychology assessment: 1) His attention and concentration has improved by 25%. Previously his remedial educator would take him in a group session as he would do an activity only under a competitive spirit whereas now he can even study alone. 2) Eye contact has improved. 3) His quantity and quality of vocabulary has improved about 25%. 4) Now, he is able to form sentences of 4-5 words whereas previously his speech was bisyllables. 5) Now he is able to formulate meaningful sentences and have a meaningful conversation. 6) Now he is learning new mathematical concepts and mother and teachers feel that study wise there are real good improvements. 7) Memory has improved ie now he is able to reproduce and recollect whatever has been taught to him in the school. 8) Speech therapist mentioned that he now does not require speech therapy whereas he now requires OT and remedial education. 9) Social interaction is better ie now he can initiate and engage himself and other people into an activity or conversation ...

By: neurogenbsi

Read the original post:
Autism Improvement After Stem Cell Therapy in Mumbai India - Video

Stem Cell Therapy For Your Pet | Las Vegas, Nevada | Dr. Roger A. Mauer DVM
veterinary-stemcell.com Dr. Mauer is very excited to now be offering Stem Cell Therapy. This innovative and affordable treatment has been making news all over the country. This treatment is completely natural and there are no side effects other than occasional minor swelling at injected joint sites. Most animal owners see results in just days after treatment and their pets benefiting with less or no pain. Stem cells are the body #39;s repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc.

By: Roger Mauer

Read the rest here:
Stem Cell Therapy For Your Pet | Las Vegas, Nevada | Dr. Roger A. Mauer DVM - Video

Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues
She is a known case of Mental Retardation with history of full term normal delivery, but mother had malaria during pregnancy. She had delayed motor milestones but achieved. She had delay mainly in speech. So she was tested and diagnosed to have MR. Gradually, she developed abnormal behavior and hyperactivity. Neurologically, she has near normal tone, reflexes and muscle power. On examination: She is hyperactive. She has poor social interaction and poor social skills. She has poor attention span. She has aggressive behavior. She is unable to read and write, but goes to a special school. She is unable to follow commands and has delayed speech. She needs assistance in all ADL. After Stem Cell Therapy OT assessment: 1) Hyperactivity has reduced by 30-40%. Now she can sit at one place if activity is of interest for 1-2 hours. She has calmed down a lot. 2) Attention and concentration has improved. Now she follows commands or instructions given. Does not need repetitions. 3) Concepts have improved, recognizes objects, matching colours, alphabets, numbers. 4) Speech is clearer and responses are relevant to questions asked. She sometimes still has repetitive speech or speaks sentences not appropriate to the present situations. 5) Aggressive behaviours have decreased. Initially the first month after SCT -- she showed increased aggressiveness towards younger brother. She would beat her brother for no reason. That slowly reduced. Now rarely does it (only when very angry). 6 ...

By: neurogenbsi

Read the rest here:
Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues - Video

Stem Cell Therapy for Left Hemiplegia Stroke
He is a case of right MCA infarct with left hemiplegia since 2009. He was treated conservatively and is able to walk independently, but not able to use left upper extremity. Neurologically, he is hypertonic and hyperreflexic on the left side. On examination: he has grade 3 voluntary control in left lower extremity and walks with aid of a stick. He has hemiplegic gait. Left upper limb voluntary control is poor with spaticity grade 3 in shoulder. On Modified Ashworth Scale spasticity on left side is grade 4. He has normal speech and bowel /bladder control. After Stem Cell Therapy 1) Spasticity has reduced in all muscle of left UE and LE. 2) He can raise his left shoulder upto 100° of range which he couldn #39;t do before. 3) Previously, he used to stretch his left hand only in the morning but now he can do the same throughout the day. 4) He can climb stairs without any support. 5) Balance while standing, walking and stair climbing has improved. 6) Now he can maintain tandem stance for 20 sec without losing balance. 7) He can do marching with leg in standing which he couldn #39;t do before. 8) VC grading : elbow 3 knee 4 Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Originally posted here:
Stem Cell Therapy for Left Hemiplegia Stroke - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dd7jnv/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Companies Mentioned

Read more:
Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3
Stem cell therapy for osteoarthritis using adipose (fat) stem cell. Case study of 76 year-old man with osteoarthritis in his knees. Stromal vasular fraction treatment statistics including side effects collected over 800 infusions. Stem cell treatments for sports injuries and why pro sports stars are seeking treatment. Case study of a professional dancer with knee and neck problems who returned to competition after stem cell treatment in Panama.

By: cellmedicine

Go here to see the original:
Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3 - Video

SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ --Bioheart, Inc. (BHRT.QB) will present an update on 12 years of clinical data on MyoCell for treating heart failure at the 8th Annual Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center - http://celltherapy.crf.org/register.html - Course Director, Warren Sherman, M.D.

(Logo: http://photos.prnewswire.com/prnh/20130107/FL37699LOGO )

Howard J. Leonhardt, Founder and Chief Technology Officer of Bioheart, will present data from clinical trials sponsored by the company since 2001.

In Phase II/III clinical trials stage in the U.S. for muscle stem cells for treating advanced heart failure, Bioheart's MyoCell is believed to be the only cell type able to create new contractile muscle in heart scar tissue.Phase II/III Part I interim results demonstrated 95.7 meters improvement in exercise capacity in Bioheart MyoCell patients over placebo (-4 meters) in a double blind randomized study.This compares to -4 meters for CHF drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells, 52 meters for adipose derived cells and 10 meters allogeneic bone marrow derived cells.

Leonhardt will also provide a look at new generation improvements brought forward to enhance cell transplantation by Bioheart which include:SDF-1 gene transfection, electrical stimulation see http://www.myostimpacers.com, repeat injections, and nutrient hydrogel.

Founded in 1999, Bioheart is one of the original cell therapy companies.Since that time, more than 400 heart failure patients have been enrolled in various myoblast therapy clinical trials worldwide. 84% percent of Bioheart MyoCell treated patients have improved while only 16% have worsened. In placebo and control groups 69% of patients have worsened.

130 more patients are needed to complete the randomized, double blinded, placebo controlled MARVEL trial.MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

View original post here:
Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost
stemcellmalaysia.com Stem cell therapy is not a cheap medical treatment. In fact, it is very expensive treatment to the majority of people. The high price of stem cell therapy becomes not only a deterrent to the majority but also creates room for non-medical sector to fill the void of demands for disease treatment. This video addresses the issues surrounding the cost of stem cell therapy, particularly in Malaysia. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.com

By: stemcells2012

Read more from the original source:
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost - Video

Stem Cell Therapy at IMC Dr.Omar Gonzalez
New Project 70

By: OmarGonzalezMD

Excerpt from:
Stem Cell Therapy at IMC Dr.Omar Gonzalez - Video

Animal Stem Cell Therapy
Dr Tim O #39;neill DVM hard at work showing you the amazing results of stem cell and Platlete Rich Plasma treatment.From:Greg SantiniViews:0 0ratingsTime:01:03More inPets Animals

Continued here:
Animal Stem Cell Therapy - Video

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient.

"We are delighted to report that the safety profile of Cx611 appears to be excellent," said Eduardo Bravo, CEO of TiGenix. "We have recruited patients who have failed at least two biologicals. If, in addition to this promising safety data, we can demonstrate a first indication of efficacy in this difficult to treat patient population, we will have a strong rationale to move forward with this product. We are looking forward to reporting the final results of the study at the end of April 2013."

About TiGenix

TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Link:
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells ...

ROCKVILLE, Md., Dec. 10, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the International Symposium on ALS/MND in Chicago, sponsored by the Motor Neurone Disease Association. In a Thursday presentation, "RESULTS OF PHASE 1 TRIAL OF SPINAL CORD TRANSPLANTATION OF NEURAL PROGENITOR CELLS IN ALS (THE NEURALSTEM, INC. TRIAL)," Dr. Glass revealed that researchers were able to establish the long-term survival of Neuralstem's transplanted spinal cord stem cells in autopsied patients, through a technology called DNA fingerprinting. Dr. Glass, who is the principal site investigator of the trial at Emory, also announced that the study team has received a grant from the National Institutes of Health (NIH) to cover a majority of the cost of an upcoming Phase II trial.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are quite pleased by our ability to perform all of the surgeries planned for the Phase I trial without evidence of significant surgical or medical complications, including those patients who received both lumbar and cervical transplantations," said Dr. Glass. "We can also report that we found evidence of cell survival in all of the patients who came to autopsy, including our first patient who died 30 months after transplantation.

This is very positive news, supporting our plan to accelerate this study by increasing the dose of stem cells delivered to the cervical spinal cord in the hopes of delaying respiratory failure and prolonging life. The next phase of the study has been partially funded by a generous grant from the National Institutes of Health, and we will begin once the FDA approves our new protocol," Dr. Glass concluded.

"This is a major finding," said Karl Johe, Ph.D., Neuralstem Chairman of the Board and Chief Scientific Officer. "There is currently no way to confirm the survival of the cells in patients while they are alive. Levels of functional recovery, or a slowdown in the progression of the disease in various patients, have given us reason to believe the cells have survived. Now, cell survival has been demonstrated by definitive evidence.

Among the six patients autopsied (five died of ALS disease progression and one, of unrelated heart failure), the survival period, from stem cell transplantation to death, ranged from 196 921 days. Five of these patients had discontinued all immune suppression medications for 57 638 days prior to death, but showed the stem cell DNA content in the range of 0.67% - 5.4% of total DNA in some spots of cord treated with the stem cells. There was no correlation of DNA content to survival period without immune suppression medication. These data, therefore, suggest that long-term immuno suppression of patients is not required for long-term survival of our cells, which points towards the feasibility of needing only transient immune suppression in future ALS trials," Dr. Johe concluded.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD).Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

Read more:
Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND

Stem Cell Therapy and Medical Tourism: Of Promise and Peril?
From:harvardstemcellViews:2 0ratingsTime:01:15:50More inScience Technology

Excerpt from:
Stem Cell Therapy and Medical Tourism: Of Promise and Peril? - Video

Gordon Camp (Parkinson #39;s Disease) Stem Cell Therapy
New Project 46From:OmarGonzalezMDViews:0 0ratingsTime:06:29More inScience Technology

Read more:
Gordon Camp (Parkinson's Disease) Stem Cell Therapy - Video

CARLSBAD, CA--(Marketwire - Nov 29, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on the development of therapeutic products, today announced the achievement of a critical milestone towards the clinical development of its stem cell therapy.

The Company's research and development team has created the world's first human clinical-grade stem cell lines with the ability to immune-match millions of individuals. ISCO's existing research-grade parthenogenetic stem cell lines, one of which contains the most common immune type in the Caucasian population and may be an immune-match to approximately 70 million people, are used in pre-clinical development. These new clinical-grade stem cell lines position ISCO to be able to conduct clinical trials in the United States.

Dr. Semechkin, CEO and Co-Chairman of the Board, comments, "We've been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and I'm excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. I'm optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide."

The new stem cell lines, created using ISCO's proprietary technology, are the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is extremely important as it means that the cells can be used in clinical development programs.

The new lines have been confirmed by independent third-party testing to be "homozygous" in the HLA coding regions meaning that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection. This feature is one of the most important differences of hpSC when compared with embryonic stem cells and a distinct clinical advantage because of their ability to be immune-matched to the patient. We expect the new lines to immune-match millions of individuals, and will be added to ISCO's existing bank providing a platform from which to develop cells and tissue for clinical use.

"The importance of this breakthrough cannot be overstated," commented Dr. Craw, Executive Vice President of ISCO. "Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

The rest is here:
International Stem Cell Corporation Announces Significant Progress Towards Clinical Development